GlaxoSmithKline PLC Corporate executive team changes (5835U)
19 January 2017 - 6:00PM
UK Regulatory
TIDMGSK
RNS Number : 5835U
GlaxoSmithKline PLC
19 January 2017
Issued: Thursday 19 January 2017, London UK - LSE
Announcement
Abbas Hussain to leave GSK
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Abbas
Hussain, President, Global Pharmaceuticals has decided to leave the
company. He has agreed with GSK that he will leave the company
later this year.
Abbas joined GSK in 2008 and has held roles of increasing
responsibility within the company's pharmaceutical business. He is
a member of GSK's executive team and a board member of ViiV
Healthcare.
Under his leadership, pharmaceutical and vaccine commercial
performance in the US and European businesses has significantly
improved, and the company has delivered a series of successful new
product launches. At the last reported quarter, new pharmaceutical
sales represented 25% of total pharmaceutical sales.
He has also built the world's leading emerging markets
pharmaceuticals business by volume, and implemented a flexible
approach to pricing across developing countries, helping GSK top
the Access to Medicine Index each time since its 2008 launch.
Abbas successfully led the implementation of GSK's new
commercial operating model across more than 100 countries, bringing
increased transparency to GSK's interactions with healthcare
professionals.
Sir Andrew Witty, CEO, GSK commented, "In his time at GSK Abbas
has proven himself to be one of the most talented and authentic
leaders in the healthcare industry. I am personally grateful for
his tremendous energy and support as a member of our executive
team. Succession processes are challenging for everyone involved
and, unfortunately, it is rare that all of those involved stay with
the company. I wish him well in his future and thank him for the
significant contribution he has made to GSK and the lives of many
patients around the world."
-Ends-
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
GSK enquiries:
UK Media enquiries: David Mawdsley +44 (0) 20 (London)
8047 5502
Simon Steel +44 (0) 20 (London)
8047 5502
Anna Carruth +44 (0) 20 (London)
8047 5502
US Media enquiries: Sarah Alspach +1 202 715 (Washington,
1048 DC)
Sarah Spencer +1 215 751 (Philadelphia)
3335
Analyst/Investor Sarah Elton-Farr +44 (0) 20 (London)
enquiries: 8047 5557
Tom Curry + 1 215 751 (Philadelphia)
5419
Gary Davies +44 (0) 20 (London)
8047 5503
James Dodwell +44 (0) 20 (London)
8047 2406
Jeff McLaughlin +1 215 751 (Philadelphia)
7002
Inside information
The information contained in this announcement is inside
information. If you have any queries on this, then please contact
Victoria Whyte GSK Company Secretary (responsible for arranging the
release of this announcement) at GSK House Brentford, Middlesex,
TW8 9GS on +44 208 047 5000.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking
statements or projections made by GSK, including
those made in this announcement, are subject
to risks and uncertainties that may cause actual
results to differ materially from those projected.
Such factors include, but are not limited to,
those described under Item 3.D 'Risk factors'
in the company's Annual Report on Form 20-F for
2015.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUKVNRBBAAARR
(END) Dow Jones Newswires
January 19, 2017 02:00 ET (07:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024